Lycopene intake (~5 mg/kg) reveals its potential in mitigating hepatocellular cancer (HCC) by reducing mitochondrial anomalies, micronucleated cell scores, reactive oxygen species, lipid peroxide levels, liver enzymes, tumor proliferation, cyclin D1, PCNA, hexokinase, aldose, phosphoglucoisomerase, and glucose‐6‐phosphate (Ibrahim et al. 2021; You et al. 2021). This evidence concerns the gene PCNA and hepatocellular carcinoma.